Back to SAMUEL Didier

Didier SAMUEL

Professor Didier Samuel / Dean of the Faculty of Medicine Paris Sud / Head of the Liver and Intensive Care Units / Director of Inserm Research Unit 1193 / Medical Director of the Liver Transplant Program

France

City: Villejuif

Institution: Centre Hepatobiliaire - Hôpital Paul Brousse - Groupe Hospitalier Paris Sud - DHU Hepatinov

Contact: didier.samuel@pbr.aphp.fr


Biography of Didier SAMUEL

Dr. Didier Samuel, MD, PhD, is Professor of Hepatology and Gastroenterology at Université Paris-Sud, Villejuif, France. Prof Samuel is also Medical Director of the Liver Transplant Program, and Head of both the Liver and Intensive Care Units at Centre Hepatobiliaire of Universitary Hospital Paul Brousse in Villejuif. He was Head of the Departments of Diseases of the Liver and of Digestive and Urinary System at Paris Sud Universitary Hospitals from 2011 to 2017. In addition, he is Director of Inserm Research Unit 1193 at Université Paris Sud. Prof Samuel obtained his MD in 1985 and his PhD in 1994 from Université Paris-Sud, and served his internship at Hôpitaux de Paris. He is currently Dean of the Faculty of Medicine Paris Sud. His research focuses on liver transplantation, viral hepatitis, HIV, liver failure and hepatocellular carcinoma. He is a member of the Council of the International Liver Transplantation Society (ILTS, acting asPresident 2013-2014), the American Association for the Study of Liver Diseases (AASLD), and European Association of the Study of the Liver (EASL, he was member of the Scientific Committee 2000-2003). He served as Editor-in-Chief of Journal of Hepatology (2010-2014). Prof Samuel has published over 400 articles in peer-reviewed scientific journals and textbooks, with a H-index of 66 and has given over 300 lectures at international congresses. In 2007, he was honored with the AASLDAchievement in Liver Transplantation Award. In 2010 he was awarded in France with the Legion d’Honneur and in 2014 with the Research Prize Allianz-Fondation de France.

PHC's participations

Tuesday, March 28th 2023

Covid-19 and end-stage liver disease -

Tuesday, March 09th 2021

HCC: EVOLVING CONCEPTS IN THERAPY (chairman)

Changing indications for liver transplantation

13th PHC – 2020

Tuesday, January 14th 2020

END STAGE LIVER DISEASE (chairman)

12th PHC – 2019

Monday, January 14th 2019

LUNCH WORKSHOPS - 3-Optimal management of HCC: Room 251 (chairman)

Tuesday, January 15th 2019

HCC Session (chairman)

Jeunes Hépatologues Conférence

Friday, June 30th 2017

Controverses (chairman)

DAY 1 – Friday, August 28

Friday, August 28th 2015

Controversies in the management of cirrhosis (chairman)

Workshop 1: Non invasive methods for fibrosis in the management of cirrhosis (chairman)

1st PHC – 2004

Friday, September 10th 2004

Treatment of Hepatitis C in Liver Transplant Patients (chairman)

2nd PHC – 2007

Monday, January 22nd 2007

Treatment pre- and post-transplantation -

3rd PHC – 2009

Tuesday, January 20th 2009

(chairman)

4th PHC – 2011

Tuesday, January 18th 2011

Difficulties faced in severe reactivation

5th PHC – 2012

Monday, January 30th 2012

Pre and post liver transplantation -

6th PHC – 2013

Monday, January 14th 2013

Transplant patients

7th PHC – 2014

Monday, January 13th 2014

Interactive luncheons - Room 5 (chairman)

Transplant patients -

11th PHC – 2018

Tuesday, January 16th 2018

Luncheon Workshops - (chairman)

HCC SESSION  (chairman)

The impact of DAAs on HCC occurence -

10th PHC – 2017

Tuesday, January 31st 2017

END-STAGE LIVER DISEASE (chairman)

Reconsidering OLT to treat HCC in an era of donors shortage -

8th PHC – 2015

Monday, January 12th 2015

Lunch Workshops - Room 252B (chairman) -

DAAs and transplant patients -

9th PHC – 2016

Monday, January 11th 2016

Lunch Workshops - Room 251 (chairman)

DAAs and transplanted patients -